The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy.

Authors:
Wang T; Lin F; Huang Y; Qian G; Yu W and 4 more

Journal:
Cancer Manag Res

Publication Year: 2022

DOI:
10.2147/CMAR.S378264

PMCID:
PMC9547547

PMID:
36217441

Journal Information

Full Title: Cancer Manag Res

Abbreviation: Cancer Manag Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The authors declare no conflicts of interest in this work."

Evidence found in paper:

"The study was funded by the National Natural Science Foundation of China (grant number 81900189). The funder had no role in the study design, data collection or analysis. The corresponding authors had full access to the data and had final responsibility for the decision to submit the manuscript for publication."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025